Moderna(MRNA) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Initiated three new clinical studies evaluating Moderna's investigational individualized neoantigen therapy in combination with Merck's Keytruda® for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinoma Advanced three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials as announced at Vaccines Day investor event CAMBRIDGE, MA / ACCESSWIRE / May 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported f ...